<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079950</url>
  </required_header>
  <id_info>
    <org_study_id>CAM-9009</org_study_id>
    <nct_id>NCT00079950</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enzon Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enzon Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Pegamotecan
      (Peg-Camptothecin) in patients with Advanced or Metastatic Soft Tissue sarcoma.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>August 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Sarcoma, Soft Tissue</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegamotecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of soft tissue sarcoma with
             measurable disease.

          -  Target tumors outside prior radiation field(s).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

          -  Adequate hematologic profile, as determined by hemoglobin, platelet, and neutrophil
             count.

          -  Adequate renal function

          -  Adequate liver function

          -  No history of hemorrhagic cystitis or evidence of microscopic hematuria

          -  Capable of understanding the protocol requirements and risks and providing written
             informed consent.

          -  Either 0 or 1 prior chemotherapy regimens

        Exclusion Criteria:

          -  Subject has a diagnosis of gastrointestinal stromal tumors.

          -  Concurrent serious medical illness unrelated to tumor within the past 6 months.

          -  Known chronic infectious disease, such as AIDS or hepatitis.

          -  Positive screening pregnancy test or is breast-feeding.

          -  A female or male subject of reproductive capacity unwilling to use methods appropriate
             to prevent pregnancy during the course of this study.

          -  Receiving concurrent chemotherapy, radiotherapy, or surgery, or has received wide
             field radiation within the previous 4 weeks.

          -  History of another active malignancy (except non-melanoma skin cancer and carcinoma in
             situ of the cervix), unless in complete remission and off all therapy for that disease
             for the last 2 years.

          -  Known or clinically suspected brain metastases.

          -  Received more than one prior treatment regimen (excluding adjuvant or neoadjuvant
             therapy) for soft tissue sarcoma.

          -  Received any investigational drug within the last 30 days.

          -  Not fully recovered from any prior surgery (at least 4 weeks recovery period for major
             surgery), and from any reversible side effects related to the administration of
             cytotoxic chemotherapy or radiation therapy.

          -  Received a prior camptothecin analog (e.g., topotecan, irinotecan).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Century City Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology Hematology Association</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Drug Development Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2004</study_first_submitted>
  <study_first_submitted_qc>March 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2004</study_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2012</last_update_posted>
  <responsible_party>
    <name_title>Senior Director, Regulatory Affairs</name_title>
    <organization>Enzon Pharmaceuticals</organization>
  </responsible_party>
  <keyword>soft</keyword>
  <keyword>sarcoma</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

